Dose-response studies with multiple endpoints can be formulated as closed testing or partition testing problems. When the endpoints are primary and secondary, whether the order in which the doses are to be tested is pre-determined or sample-determined lead to different partitioning of the parameter space corresponding to the null hypotheses to be tested. We use the case of two doses and two endpoints to illustrate how to apply the partitioning principle to construct multiple tests that control the appropriate error rate. Graphical representation can be useful in visualizing the decision process.
identify the best dose to use in confirmatory Phase III trials. While this has been the framework for several decades, there are still many drugs that fail to confirm efficacy and safety in Phase III (estimates range from 30-50%) with a substantial number of failures attributed to improper dose selection. Thus, the importance of the design and analysis of dose response studies is as relevant today as it has ever been.
In the past, efficacy of a new drug was typically demonstrated by showing its superiority to a placebo (called a negative control). However, in recent years, when treatments known to be effective exist, and the disease does not cause mortality or irreversible morbidity, efficacy of a new drug might be defined as superiority or non-inferiority to a known effective treatment (called an active control). In the case of non-inferiority trials, the determination of non-inferiority might be based on what is a clinically meaningful difference. See [1] . Even in the case of superiority trials against a negative control, the definition of superiority might consider risk versus benefit, if there is toxicity concerns for the drug. (see [2] .) Some early discussion of these concepts can be seen in [3, 4, 5, 6] .
Dose-response studies may have multiple endpoints. A primary endpoint is one such that efficacy of a new drug relative to the control in this single endpoint constitutes evidence of efficacy.
Secondary endpoints are ones that efficacy of a new treatment in any secondary endpoints supports evidence of efficacy, but by themselves (i.e. in the absence of efficacy in a primary endpoint) do not constitute evidence of efficacy.
When there are primary and secondary endpoints, inference on the secondary endpoint is given only if the compound is efficacious for the primary endpoint at that dose. This ordering guides the selection of test statistics for each intersection hypothesis in closed testing (as in [7] ). We give a different perspective in this article, which is the ordering guides the partitioning of the parameter space in using the partitioning principle to construct multiple tests that control the appropriate FWER.
In some (but not all) dose-response studies, it may be appropriate to pre-determine the order in which inferences on the doses are given. For example, one might start with the high dose and proceed to inference on the low dose only if the high dose shows efficacy. We show how this second "ordering" further guides the partitioning of the parameter space. The resulting partitioning test is in the form of a decision tree which can be represented graphically.
Interestingly, the joint distribution of t test statistics for multiple endpoints is not what is usually called the multivariate t distribution. This article discusses the computation of this distribution in the bivariate case which, to avoid confusion, we call the dual t distribution. We show, for example, that using algorithms for multivariate t distributions results in slightly liberal critical values, while computing as if the t statistics were independent results in somewhat conservative critical values. Section 2 gives a motivating example of a dose-response study with multiple endpoints. Section 3 shows how the partitioning principle forms null hypotheses when inferences are ordered by dose, and the corresponding multiple test is a step-down test. Section 4 extends the partitioning principle of forming null hypotheses to when inferences are ordered by dose and by endpoint. The corresponding multiple test has a graphical representation. That section also contains a study of issues in the computation of critical values. Section 5 provides a numerical illustration of methods developed in this article, using the real data example in section 2.
A motivating example for dose-response studies
Consider, for example, [8] , a 26-center double-blind trial comparing the effect of five doses of the anti-psychotic drug "Seroquel" (Quetiapine) and the placebo with parallel design on a total of 361 patients. For illustration purpose, we will focus on two of the doses (75 mg/day and 600 mg/day) with the primary endpoint being Clinical Global Impression (CGI) Global Improvement score and the secondary endpoint being CGI Severity of Illness score. Summary statistics for these two doses and endpoints are presented in Table 1 . Throughout the paper, the placebo (0 mg/day), low dose (75 mg/day) and high dose (600 mg/day) groups will be indexed as i = 0, 1, 2. Primary and secondary endpoints will be indexed by superscripts L = P, S. For discussion involving only the primary endpoint, the superscript P will be dropped for convenience.
Let µ
as the true mean difference between dose group i and the placebo for endpoint L,
The family of null hypotheses of interest consists of four null hypotheses with the first two in (1) concerning primary endpoint and the second two in (2) concerning secondary endpoint.
Assume the samples from dose group
where
The purpose of dose-response studies is to find which doses are effective. Control of multiple testing error rate should control the probability of incorrectly inferring a dose is efficacious for some endpoint when in fact it is not. In this situation, controlling the False Discovery Rate (FDR)
will not control this probability (see [9] ), while controlling the Familywise Error Rate (FWER) strongly for appropriately formulated null hypotheses will. We thus consider methods that strongly control FWER in this article.
With four null hypotheses in (1) and (2) 
Closed testing to step-down doses according to sample responses
The closed testing technique of [10] tests all possible non-empty intersections of the hypotheses in (1), leading to the three hypotheses in (5), each at level-α:
The logical implications of testing are: • If all three hypotheses are rejected, then infer both doses are efficacious.
We use t-statistics T 1 and T 2 defined in (4) (with superscript P dropped) to test the three intersection hypotheses in (5) (2) denote the random indices such that T (1) < T (2) , then the rejection rules can be shown in Table 2 . 
Since the critical values satisfy d α,2,ν > t α,ν , a step-down procedure with sample-determined steps exists, as follows: (2) is efficacious and go to step 2; else stop.
• Step 2: If T (1) > t α,ν , infer dose (1) is efficacious and stop; else stop.
Partition to step-down doses
If higher dosage is expected to be more efficacious, then one may choose to always test the high dose first. If high dose is effective, then proceed to test low dose; otherwise, stop. We can formally state this pre-determined sequence of testing as:
Condition A (order in doses): The low dose can not be claimed efficacious unless the high dose has shown evidence of efficacy.
The partitioning principle of [11] and [12] is a general principle for constructing multiple tests.
Under condition A, [13] partition the null space, {θ ∈ R
|θ 2 ≤ δ} and {θ ∈ R 2 |θ 1 ≤ δ and θ 2 > δ} corresponding to the two hypotheses:
The logical implications of testing are:
, then no inference is given, since "neither dose is efficacious" (which is contained in H ↓ 02 ) is not rejected.
• is "either low dose or high dose is not efficacious", the implication is "both high dose and low dose are efficacious".
• 
as shown in Table 3 . 
In terms of the rejection rules in Table 3 , the pre-determined D-steps (D stands for doses) proceeds as follows.
• Step 1: If T 2 > t α,ν , infer high dose is efficacious and go to step 2; else stop.
• Step 2: If T 1 > t α,ν , infer low dose is efficacious and stop; else stop.
Note that, even though the method above controls FWER regardless of whether the shape of the true response function, it is recommended only when the response is expected to be monotonically increasing (for otherwise it might stop too soon and miss an efficacious dose).
Partition testing with two doses and two endpoints
Suppose the dose-response study has both a primary endpoint and a secondary endpoint, so that the family of null hypotheses of interest includes both those in (1) and (2). We will show that, in addition to stepping through doses, the partitioning principle can also be used to derived multiple tests that step through endpoints in a pre-determined sequence.
Partition to step-down endpoints
Multiple testing procedures for dose-response studies with a primary endpoint and hierarchically ordered secondary endpoints were developed in [7] . In the case of two doses and two endpoints (one secondary endpoint), the procedure has to satisfy the condition that for the same dose, the secondary endpoint is tested only if primary endpoint is claimed to be efficacious, which is formally stated as:
Condition B (order in endpoints): For the same dose, a secondary endpoint can not be claimed efficacious unless its primary endpoint has been shown to be efficacious.
Within each endpoint, Dunnett's method was used in [7] to adjust multiplicity for multiple doses. The FWER of the whole procedure was controlled at α using the principle of closed testing. Figure 1 is a graphical representation of their procedure with two doses and two endpoints.
The procedure in [7] can be reproduced by partitioning the parameter space with constraints on Figure 1 : Decision process in [7] Step 1:
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? ?
Step 2: 
Partitioning to step-down both doses and endpoints
The procedure developed in [7] steps through the endpoints in a pre-determined sequence, satisfying condition B, but not necessarily steps through the doses in a pre-determined sequence.
To step through both doses and endpoints, we test the following four partition hypotheses in a step-down fashion (pre-determined DE-steps):
(High dose is not effective for primary endpoint).
-If rejected, infer high dose for the primary endpoint is effective and proceed to step 2; else stop.
• Step 2: Test two hypotheses: The direction of these steps is presented in Table 4 : Proceed only if both hypotheses in step 2 are rejected
Decision tree
The rejection rules for these hypotheses in each step are presented in Table 5 in the form of usual t-statistics T L i , i = 1, 2, L = P, S, as defined in (4). are not disjoint, we need to adjust for multiplicity to make the FWER for the whole procedure controlled at level α.
The decision tree of this step-down procedure with pre-determined DE-steps is presented in Figure 2 . Step 1:
Step 2:
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Step 3: T According to Table 5 , we need to find the critical value c 2 accounted for multiplicity for the two hypotheses in step 2. That is, one needs to focus on the joint distribution of (T 
) with mean 0 = (0, 0), variance 1 and covariance
is the joint density of
Note that the definition of a bivariate t distribution, as originally introduced by [14] and computed by the ProbMC function in SAS and the qmvnorm function in the R package mvtnorm, requires the denominators in (7) to be the same random variableσ
, which is not the case here. In fact, computing (7) as if the distribution were bivariate t overestimates the probability, resulting in somewhat liberal critical values, as we will demonstrate. To avoid confusion, we call the distribution of (T
(This distribution was studied by [15] .)
The probability (8) Bivariate t distribution
σ S are perfectly correlated, or they are the same, the situation coincides with the bivariate t case. Specifically, the probability in (7) reduces to
where γ ν (s) is the density of χ 2 ν /ν, and ν = 2 i=0 (n i − 1) is the degrees of freedom.
Dual t distribution
It can be shown thatσ (9) can be viewed as a simplified version of (8) .
Theorem 1 Probability (7) is greater whenσ P σ P andσ S σ S are correlated than when they are independent.
Proof of Theorem 1:
We first condition on Z 1 and Z 2 , and note c 2 > 0
Sinceσ P σ P andσ S σ S are associated (see Theorem 6.1, [16] ), for any given Z 1 and Z 2
The result follows.
Independent t statistics T
To further break down the four dimensional integral in (9), we add the assumption of indepen-
2 ) in addition to independent denominators, which is reasonable since the correlation between Z 1 and Z 2 is only ρ/2 in the balanced case. This method is more conservative then the previous method as shown in Theorem 2. 
Proof of Theorem 2:
Assume independence ofσ
By Slepian's inequality (Corollary A.3.1 on p. 229 of [17] )
The degrees of conservatism for the methods introduced above are compared in terms of critical value c 2 for different combinations of correlation between endpoints ρ and error degrees of freedom ν in Table 6 . Critical values for the dual t and independent standard errors methods are based on 100,000 simulations.
As shown in Table 6 , for each combination of ρ and ν, the normal approximation is somewhat liberal and the bivariate t approximation is slightly liberal. Assuming independence ofσ
is slightly conservative, while assuming independence of t statistics is somewhat conservative. It should be noted that, in the setting of simultaneous efficacy and safety studies, [19] considered f Wishart is generated first using Bartlett's decomposition and then appropriately transformed (see [18] ).
g The bivariate normal quantiles are obtained by qmvnorm of R package mvtnorm.
19
using the Bonferroni inequality and the bootstrap technique to compute such probabilities.
Analysis of the anti-psychotic drug data
We illustrate the step-down procedure with pre-determined DE-steps using the anti-psychotic drug example introduced at the beginning of the paper with δ P = δ S = 0. Using pooled standard error from these three groups, the t-statistics corresponding to each dose and endpoint and the error degrees of freedom are:
If we want to control the FWER at 5% level, then c 1 = t .05,151 = 1.6550, while c 2 = 1.9702, based on the independent t method (which is appropriate because the correlation is unknown).
Note in this particular example, a lower score indicates better drug effect. To make it consistent with our hypotheses set up, we take the negatives of the t-statistics and then apply our procedure.
• Step 1: Is 3.7318 > 1.6550? Yes, go to step 2.
• Step 2: Is 1.7499 > 1.9702 or 0.4212 > 1.9702? No, stop.
So infer high dose (600 mg/day) is efficacious for primary endpoint only, and no evidence of efficacy can be made for low dose (75 mg/day).
Conclusion
In this paper, we present a systematic way of constructing null hypotheses by partitioning the parameter space according to conditions that order inferences by dose (high to low), or endpoint (primary to secondary), or both. The hypotheses so constructed automatically form step-down procedures (pre-determined D-steps, E-steps, or DE-steps) and control the proper error rate at a pre-specified level. This way of tests construction can be generalized to situations with k > 2 doses and m > 2 endpoints. The technique is as follows. Start by writing down the null hypotheses whose rejections correspond to desired inferences on primary and secondary endpoints. Then, following stated conditions for the decision process, make each null hypothesis in a subsequent step disjoint from null hypotheses in previous steps (by removing from it the union of the null hypotheses whose rejections lead up to it). Adjust for multiplicity within a step (only) if the null hypotheses are not disjoint, but do not adjust for multiplicity between steps.
An important issue in multiple endpoints problems is how to deal with correlations among the test statistics induced by correlations among measurements on the multiple endpoints. We made a systematic study of liberalism and conservatism of five approximation methods. . . . . . . , whereσ
. To obtain the joint distribution of (σ 
